tetano
Editor, Senior Moderator
Clin Microbiol Rev
. 2020 Aug 12;33(4):e00072-20.
doi: 10.1128/CMR.00072-20. Print 2020 Sep 16.
Convalescent Plasma Therapy for COVID-19: State of the Art
Daniele Focosi[SUP] 1 [/SUP], Arthur O Anderson[SUP] 2 [/SUP], Julian W Tang[SUP] 3 [/SUP], Marco Tuccori[SUP] 4 5 [/SUP]
Affiliations
Abstract
SUMMARYConvalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared with historical usage, pathogen reduction technologies have now added an extra layer of safety to the use of CP, and new manufacturing approaches are being explored. This review summarizes historical settings of application, with a focus on betacoronaviruses, and surveys current approaches for donor selection and CP collection, pooling technologies, pathogen inactivation systems, and banking of CP. We additionally list the ongoing registered clinical trials for CP throughout the world and discuss the trial results published thus far.
Keywords: Ebola virus disease; Middle East respiratory syndrome; SARS; antibody-dependent enhancement; convalescent blood product; convalescent plasma; convalescent whole blood; coronavirus disease 2019; enzyme-linked immunosorbent assay; intravenous immunoglobulins; plaque reduction neutralization test.
. 2020 Aug 12;33(4):e00072-20.
doi: 10.1128/CMR.00072-20. Print 2020 Sep 16.
Convalescent Plasma Therapy for COVID-19: State of the Art
Daniele Focosi[SUP] 1 [/SUP], Arthur O Anderson[SUP] 2 [/SUP], Julian W Tang[SUP] 3 [/SUP], Marco Tuccori[SUP] 4 5 [/SUP]
Affiliations
- PMID: 32792417
- DOI: 10.1128/CMR.00072-20
Abstract
SUMMARYConvalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared with historical usage, pathogen reduction technologies have now added an extra layer of safety to the use of CP, and new manufacturing approaches are being explored. This review summarizes historical settings of application, with a focus on betacoronaviruses, and surveys current approaches for donor selection and CP collection, pooling technologies, pathogen inactivation systems, and banking of CP. We additionally list the ongoing registered clinical trials for CP throughout the world and discuss the trial results published thus far.
Keywords: Ebola virus disease; Middle East respiratory syndrome; SARS; antibody-dependent enhancement; convalescent blood product; convalescent plasma; convalescent whole blood; coronavirus disease 2019; enzyme-linked immunosorbent assay; intravenous immunoglobulins; plaque reduction neutralization test.